Acyclovir sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561698

CAS#: 69657-51-8 (sodium)

Description: Acyclovir sodium is an antimetabolite. It inhibits HSV-specified DNA polymerases and prevents further viral DNA synthesis without affecting the normal cellular processes.

Chemical Structure

img
Acyclovir sodium
CAS# 69657-51-8 (sodium)
Instruction

Theoretical Analysis

Hodoodo Cat#: H561698
Name: Acyclovir sodium
CAS#: 69657-51-8 (sodium)
Chemical Formula: C8H10N5NaO3
Exact Mass: 0.00
Molecular Weight: 247.180
Elemental Analysis: C, 38.87; H, 4.08; N, 28.33; Na, 9.30; O, 19.42

Price and Availability

Size Price Availability Quantity
1g USD 185 2 Weeks
2g USD 250 2 Weeks
5g USD 450 2 Weeks
Bulk inquiry

Related CAS #: 69657-51-8 (sodium)   59277-89-3 (free)  

Synonym: Acyclovir sodium; Aciclovir sodium;

IUPAC/Chemical Name: Sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate

InChi Key: RMLUKZWYIKEASN-UHFFFAOYSA-M

InChi Code: InChI=1S/C8H11N5O3.Na/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14;/h3,14H,1-2,4H2,(H3,9,11,12,15);/q;+1/p-1

SMILES Code: [O-]C1=C2N=CN(COCCO)C2=NC(N)=N1.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 247.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Caviness AC, Demmler GJ, Swint JM, Cantor SB. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates. Arch Pediatr Adolesc Med. 2008 Jul;162(7):665-74. doi: 10.1001/archpedi.162.7.665. PubMed PMID: 18606938.

2: Jain SK, Gupta Y, Jain A, Rai K. Enhanced transdermal delivery of acyclovir sodium via elastic liposomes. Drug Deliv. 2008 Mar-Apr;15(3):141-7. doi: 10.1080/10717540801952407 . PubMed PMID: 18379926.

3: Jain SK, Jain RK, Chourasia MK, Jain AK, Chalasani KB, Soni V, Jain A. Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech. 2005 Sep 20;6(1):E35-41. PubMed PMID: 16353961; PubMed Central PMCID: PMC2750409.

4: Ling J, Gupta VD. Stability of acyclovir sodium after reconstitution in 0.9% sodium chloride inection and storage in polypropylene syringes for pediatric use. Int J Pharm Compd. 2001 Jan-Feb;5(1):75-7. PubMed PMID: 23981803.

5: Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc (Wash). 1999 Jul-Aug;39(4):514-8. PubMed PMID: 10467816.

6: Zhang Y, Trissel LA, Martinez JF, Gilbert DL. Stability of acyclovir sodium 1, 7, and 10 mg/mL in 5% dextrose injection and 0.9% sodium chloride injection. Am J Health Syst Pharm. 1998 Mar 15;55(6):574-7. PubMed PMID: 9544334.

7: Gürses N, Kalayci AG, Işlek I, Us D. Failure of acyclovir sodium therapy in herpes simplex encephalitis. Ann Trop Paediatr. 1996 Jun;16(2):173-5. PubMed PMID: 8790683.

8: Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1995 Oct 15;52(20):2208-12. PubMed PMID: 8564592.

9: Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1995 May 15;52(10):1086-90. PubMed PMID: 7656099.

10: Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1994 Feb 15;51(4):495-9. PubMed PMID: 8017415.

11: Drago F, Romagnoli M, Loi A, Rebora A. Epstein-Barr virus-related persistent erythema multiforme in chronic fatigue syndrome. Arch Dermatol. 1992 Feb;128(2):217-22. PubMed PMID: 1310844.

12: Brayman KL, Stephanian E, Matas AJ, Schmidt W, Payne WD, Sutherland DE, Gores PF, Najarian JS, Dunn DL. Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg. 1992 Jan;127(1):38-47; discussion 47-8. PubMed PMID: 1734849.

13: Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991 Jun;18 Suppl A:317-29. Review. PubMed PMID: 1679798.

14: Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA. 1990 Mar 23-30;263(12):1662-4. PubMed PMID: 2308204.

15: Das Gupta V, Pramar Y, Bethea C. Stability of acyclovir sodium in dextrose and sodium chloride injections. J Clin Pharm Ther. 1989 Dec;14(6):451-6. PubMed PMID: 2613771.

16: Sall RK, Kauffman CL, Levy CS. Successful treatment of progressive acyclovir-resistant herpes simplex virus using intravenous foscarnet in a patient with the acquired immunodeficiency syndrome. Arch Dermatol. 1989 Nov;125(11):1548-50. PubMed PMID: 2554819.

17: Beyer CF, Arens MQ, Hill GA, Rose BT, Beyer LR, Schanzlin DJ. Oral acyclovir reduces the incidence of recurrent herpes simplex keratitis in rabbits after penetrating keratoplasty. Arch Ophthalmol. 1989 Aug;107(8):1200-5. PubMed PMID: 2547352.

18: Sergott RC, Anand R, Belmont JB, Fischer DH, Bosley TM, Savino PJ. Acute retinal necrosis neuropathy. Clinical profile and surgical therapy. Arch Ophthalmol. 1989 May;107(5):692-6. PubMed PMID: 2655568.

19: Schlossberg D, Littman M. Varicella pneumonia. Arch Intern Med. 1988 Jul;148(7):1630-2. PubMed PMID: 3382308.

20: VanLandingham KE, Marsteller HB, Ross GW, Hayden FG. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988 Feb 19;259(7):1051-3. Erratum in: JAMA 1988 May 6;259(17):2547. PubMed PMID: 3339802.